Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Confirmation of Artemisinin Partial Resistance in Plasmodium Falciparum in Ethiopia
NCT07527182Completed
- Start
- May 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of artemether and lumefantrine in malaria. Primary endpoint: Day-3 Parasite Positivity Rate. Started May 2024; status: completed.
02
Drugs
artemetherlumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07527182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527182.